U.S. Markets closed
  • S&P 500

    4,701.21
    +14.46 (+0.31%)
     
  • Dow 30

    35,754.75
    +35.32 (+0.10%)
     
  • Nasdaq

    15,786.99
    +100.07 (+0.64%)
     
  • Russell 2000

    2,271.71
    +17.92 (+0.80%)
     
  • Crude Oil

    72.70
    +0.34 (+0.47%)
     
  • Gold

    1,784.70
    -0.80 (-0.04%)
     
  • Silver

    22.44
    +0.01 (+0.04%)
     
  • EUR/USD

    1.1344
    +0.0072 (+0.6353%)
     
  • 10-Yr Bond

    1.5090
    +0.0290 (+1.96%)
     
  • Vix

    19.90
    -1.99 (-9.09%)
     
  • GBP/USD

    1.3205
    -0.0037 (-0.2813%)
     
  • USD/JPY

    113.7110
    +0.1710 (+0.1506%)
     
  • BTC-USD

    50,521.28
    -29.60 (-0.06%)
     
  • CMC Crypto 200

    1,320.56
    +15.44 (+1.18%)
     
  • FTSE 100

    7,337.05
    -2.85 (-0.04%)
     
  • Nikkei 225

    28,860.62
    +405.02 (+1.42%)
     

argenx SE (ARGX) Q3 2021 Earnings Call Transcript

·36 min read
argenx SE (ARGX) Q3 2021 Earnings Call Transcript
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

The Bullous Pemphigoid trial is on track to start by the end of this year, and Myositis is expected to start during the first quarter of 2022, now that we have wrapped up our FDA consultations, and these are depicted on Slides 10 and 11. Through our collaboration with Zai Lab, we are also planning to launch proof-of-concept trials in additional indications.